ReviewChest2023
Update on Biomarkers for the Stratification of Indeterminate Pulmonary Nodules.
Review in Chest, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05968898 (Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Cancer Risk Stratification of Pulmonary Nodules), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Cancer Risk Stratification of Pulmonary Nodules
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Article
- Development and validation of machine learning diagnostic models integrating clinical, CT, and laboratory features to differentiate lung cancer from pulmonary tuberculosis in patients with solitary pulmonary nodules: a single-center retrospective study.Translational lung cancer research · 2026Article
- Improving lung cancer screening diagnostic efficiency.Current opinion in pulmonary medicine · 2026Review
- Biomarkers for Lung Nodule Risk Stratification: Are We There Yet?Diagnostics (Basel, Switzerland) · 2026Review
- Clinical significance of serum levels of 14-3-3β protein in patients with non-small cell lung cancer.Scientific reports · 2026Article
- Is This Calculator Broken?: Comparative Performance of Lung Nodule Risk Assessment Calculators in a High-Prevalence Cohort.CHEST pulmonary · 2026Article
- Theoretical Clinical Utility of Advanced Practice Provider Use of an Artificial Intelligence Radiomics-based Tool for Pulmonary Nodule Evaluation and Management.CHEST pulmonary · 2026Article
- Article
- Validation of a blood-based autoantibody test to assess lung cancer risk in 4-30 mm pulmonary nodules: a retrospective pooled analysis of four cohort studies.Future oncology (London, England) · 2026Article
- Clinicians' cancer risk assessment among patients with pulmonary nodules: a qualitative study.Annals of the American Thoracic Society · 2026Article
- Article
- Longitudinal Analysis of CYFRA 21-1 Levels in Patients with Pulmonary Nodules: Differential Trajectories Between Benign and Malignant Cases and Impact of Tumor Resection.medRxiv : the preprint server for health sciences · 2026Article
- Article
- Editorial: Advancing diagnostic excellence in early lung cancer detection.Frontiers in oncology · 2026Article
- Stage- and histology-specific sensitivity for the detection of lung cancer of the NELSON screening protocol-A modeling study.International journal of cancer · 2025Article
- Biomarkers for the diagnosis of indeterminate pulmonary nodules: are we there yet?Journal of thoracic disease · 2025Review
- Simultaneous medullary thyroid carcinoma and primary non-small cell lung cancer: case report and literature review.Discover oncology · 2025Article
- Radiographic ground-glass nodules predict less aggressive features and favorable immune landscapes in early lung adenocarcinoma and its precursors.Translational lung cancer research · 2025Article
- Multiple Indeterminate pulmonary nodules (IPNs) as independent prognostic indicators in pediatric osteosarcoma: A ten-year retrospective study.Journal of bone oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Lung cancer is the leading cause of cancer-related deaths. Early detection and diagnosis are critical, as survival decreases with advanced stages. Approximately 1.6 million nodules are incidentally detected every year on chest CT scan images in the United States. This number of nodules identified is likely much larger after accounting for screening-detected nodules. Most of these nodules, whether incidentally or screening detected, are benign. Despite this, many patients undergo unnecessary invasive procedures to rule out cancer because our current stratification approaches are suboptimal, particularly for intermediate probability nodules. Thus, noninvasive strategies are urgently needed. Biomarkers have been developed to assist through the continuum of lung cancer care and include blood protein-based biomarkers, liquid biopsies, quantitative imaging analysis (radiomics), exhaled volatile organic compounds, and bronchial or nasal epithelium genomic classifiers, among others. Although many biomarkers have been developed, few have been integrated into clinical practice as they lack clinical utility studies showing improved patient-centered outcomes. Rapid technologic advances and large network collaborative efforts will continue to drive the discovery and validation of many novel biomarkers. Ultimately, however, randomized clinical utility studies showing improved patient outcomes will be required to bring biomarkers into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.